GENFIT REPORTS THIRD QUARTER 2026 FINANCIAL INFORMATION AND PROVIDES CORPORATE UPDATE
Story updates
05:00:48 PM UTC
SquawkNews
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company be
05:02:02 PM UTC
SquawkNews
Lille (France); Cambridge, (Massachusetts, United States); November 5, 2026 - GENFIT Euronext:GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its third quarter 2026 financial results1 and provid…